Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC that has obtained phase I clinical trial approval for tumors; and HER2 ADC that has carried out phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminlevulinic acid hydrochloride, which is in phase II clinical trials for cervical diseases infected by HPV, acne, and actinic keratosis. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis; and didopa controlled- release tablets, which has completed phase II clinical trial for early parkinson's disease. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.